AVAV Underperforms Industry in the Past 6 Months: What Should You Do?

AeroVironment shares have fallen 30.6% over six months, versus declines of 12.1% for its aerospace-defense equipment industry and 13.5% for the broader aerospace sector, prompting Zacks to maintain a Rank #4 (Sell). Fiscal 2027 Q1 revenue rose 6% year over year to $480.5 million and EPS increased to $0.59 from $0.32, while the company secured a more-than-$50 million international LOCUST laser-system order. However, labor and component-supply constraints, a 41.47x forward P/E versus the industry's 33.59x, and 4.04% ROE versus 15.35% for the sub-industry underpin the cautious outlook despite projected sales growth of 9.8% in fiscal 2027 and 15.8% in fiscal 2028.

Analysis

AVAV's key issue is not demand but conversion: revenue growth alongside declining full-year EPS implies mix, integration, manufacturing ramp, or program-cost pressure is absorbing the operating leverage investors expected from defense autonomy spending. At a premium earnings multiple with subpar capital efficiency, even modest gross-margin misses can produce disproportionate de-rating. The relevant near-term KPI is backlog conversion into gross profit and cash flow, not incremental awards; a directed-energy order validates product interest but is too small to alter consolidated economics absent follow-on volume.

AIR and ATRO have outperformed despite facing similar component and labor constraints, weakening the argument that industry conditions alone explain AVAV's relative underperformance. This points to company-specific execution risk and potentially a more favorable aftermarket/content mix at peers. A sustained AVAV recovery likely requires evidence over the next one to two earnings reports that procurement costs, production yields, and acquired-business integration are improving enough to restore FY28 earnings expectations rather than merely preserve revenue guidance.

The contrarian case is that counter-UAS procurement is moving from experimentation to programmatic spending, where qualification barriers can create a concentrated supplier base. That supports AVAV's 6-18 month strategic value, but the market will not pay for that option value indefinitely if margins remain deferred. Defense-budget timing and export approvals are additional catalysts, yet also create lumpy-quarter risk that makes a directional long ahead of margin confirmation unattractive.

Key Decisions for Investors

• Maintain an underweight/short bias in AVAV versus a defense peer basket over the next 1-3 months; preferred pair is short AVAV / long AIR, sized beta-neutral. Thesis is premium-multiple compression if the next report fails to show gross-margin and free-cash-flow improvement; cover on a material upward FY27/FY28 EPS revision or clear margin-guidance increase.
• Do not chase AIR or ATRO solely on relative momentum. Use a pullback or earnings confirmation to add exposure, with AIR the cleaner relative hedge against AVAV because its business mix is less dependent on a single emerging weapons category.
• Set an AVAV long-watch trigger for two conditions: backlog/bookings growth converts into improving gross margin, and FY28 consensus EPS holds or rises after the next earnings release. If both occur, reassess for a 6-18 month long targeting multiple stabilization; without them, new contract announcements are not sufficient evidence.
• For existing AVAV longs, reduce exposure before the next earnings print or protect with a 1-3 month put spread. The asymmetric risk is a revenue-guidance hold paired with margin or cash-flow disappointment, which would challenge the growth-stock valuation framework.